Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idursulfase-IT extension study in Hunter syndrome with cognitive impairment
NCT06031259Phase 3Active, not recruiting
- Sponsor
- Takeda
- Start
- Mar 2024
- Primary completion
- Jan 2029
- Modality
- Replacement Enzymes
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of idursulfase in mucopolysaccharidosis type II, sponsored by Takeda. Primary endpoints: Adverse Events at 4.8 years, Adverse Events Related to Idursulfase-IT at 4.8 years and 4 more. Started Mar 2024; status: active, not recruiting.
02
Drugs
idursulfase
03
Conditions
mucopolysaccharidosis type II
Beyond the preview
Go deeper on NCT06031259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06031259.